A0A1U7T522 (A0A1U7T522_CARSF) Carlito syrichta (Philippine tarsier) (Tarsius syrichta)
Stress-activated protein kinase JNK UniProtKBInterProSTRINGInteractive Modelling
464 aa; Sequence (Fasta) ;
9 identical sequences: Homo sapiens: P53779; Pan troglodytes: A0A2J8L2H3; Macaca mulatta: A0A1D5QMC7, A0A8J8YAK3; Macaca fascicularis: A0A2K5TUM6; Sapajus apella: A0A6J3ENL5; Fukomys damarensis: A0A091ER56; Saimiri boliviensis boliviensis: A0A2K6U2B1; Orycteropus afer afer: A0A8B7AHP2
Available Structures
61 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal Structure of JNK3 in Complex with JIP1 Peptide |
Heteromer P53779; Q9UQF2; | 100.0 | ||||
| Crystal Structure of JNK3 in Complex with SAB Peptide |
Heteromer O60239; P53779; | 100.0 | ||||
| Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor |
Heteromer P53779; Q9UQF2; | 100.0 | 1×932; | |||
| Crystal Structure of JNK3 in Complex with ATF2 Peptide |
Heteromer P15336; P53779; | 100.0 | ||||
| Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatm… |
Heteromer P53779; Q9UQF2; | 100.0 | 1×SYY; | |||
| Crystal structure of JNK3 in complex with light-activated covalent inhibitor MR-II-249 with both no… | monomer | 100.0 | 2×0EI; 9×EDO; | |||
| Crystal structure of JNK3 in complex with FMU-001-367 (compound 1) | monomer | 100.0 | 1×0G3; 20×EDO; 1×MES; | |||
| The Crystal Structure of JNK3 from Biortus. | monomer | 100.0 | 1×ANP; 1×MG; | |||
| Crystal structure of JNK3 with indazole inhibitor, SR-3737 | monomer | 100.0 | 1×JK2; 2×EDO; | |||
| Crystal structure of human JNK3 in complex with a benzenesulfonamide inhibitor. | monomer | 100.0 | 1×3EL; | |||
| Discovery of potent and selective covalent inhibitors of JNK | monomer | 100.0 | 1×CQQ; | |||
| Discovery of potent and selective covalent inhibitors of JNK | monomer | 100.0 | 1×0F0; | |||
| Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se… | monomer | 100.0 | 1×X3S; | |||
| Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopy… | monomer | 100.0 | 1×3NL; | |||
| Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se… | monomer | 100.0 | 1×X3V; | |||
| JNK2/3 in complex with N-(2-methylpyridin-4-yl)-3-{4-[(phenylcarbamoyl)amino]-1H-pyrazol-1-yl}benza… | monomer | 100.0 | 1×3HJ; | |||
| The crystal structure of inhibitor-bound JNK3 | monomer | 100.0 | 1×1RQ; | |||
| Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyri… | monomer | 100.0 | 1×BZ9; | |||
| Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor | monomer | 100.0 | 1×46C; 1×GOL; | |||
| JNK2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-… | monomer | 100.0 | 1×3H8; | |||
| Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors | monomer | 100.0 | 1×4F2; | |||
| Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors | monomer | 100.0 | 1×519; | |||
| Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se… | monomer | 100.0 | 1×X3Y; | |||
| THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR | monomer | 100.0 | 1×ANP; 1×880; 3×UNX; | |||
| N-Aromatic-Substituted Indazole Derivatives as Brain Penetrant and Orally Bioavailable JNK3 Inhibit… | monomer | 100.0 | 1×86C; | |||
| The crystal structure of AMP-bound JNK3 | monomer | 100.0 | 1×AMP; | |||
| Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor | monomer | 100.0 | 1×984; | |||
| Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451 | monomer | 99.67 | 1×JK1; 1×EDO; | |||
| THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP | monomer | 100.0 | 2×MG; 1×ANP; | |||
| JNK2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-… | monomer | 100.0 | 1×3HQ; | |||
| c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor | monomer | 100.0 | 1×255; 17×UNX; 1×TFA; 4×EDO; | |||
| Crystal structure of apo and AMP-bound JNK3 | monomer | 100.0 | ||||
| JNK3 bound to aminopyrimidine inhibitor, SR-3562 | monomer | 100.0 | 1×FMY; | |||
| Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitors | monomer | 100.0 | 1×J07; | |||
| Crystal structure of JNK3 in complex with a fragment molecule | monomer | 100.0 | 1×J6F; | |||
| The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor | monomer | 100.0 | 1×537; | |||
| JNK2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-… | monomer | 100.0 | 1×3HN; | |||
| The crystal structure of JNK3 in complex with a phenantroline inhibitor | monomer | 100.0 | 1×CL; 1×9HP; | |||
| Inhibitor complex of JNK3 | monomer | 100.0 | 1×JNK; | |||
| JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin… | monomer | 100.0 | 1×J88; | |||
| Design, synthesis, biological evaluation, and X-ray crystallography of diarylpyrazole derivatives p… | monomer | 100.0 | 1×WNK; | |||
| IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding | monomer | 100.0 | 1×JNF; | |||
| IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding | monomer | 100.0 | 1×JNO; | |||
| Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacoki… | monomer | 100.0 | 1×589; | |||
| Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor | monomer | 100.0 | 2×BME; 1×CL; 1×BGE; 1×EDO; 1×C15; | |||
| Crystal structure of JNK3 in complex with AMP-PCP | monomer | 100.0 | 1×MG; 2×NA; 1×BME; 1×ACP; 1×C15; 1×PEG; | |||
| JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moiety | monomer | 100.0 | 1×SWM; 4×EDO; 3×GOL; 1×BME; 2×PEG; 1×C15; | |||
| inhibitor complex of JNK3 | monomer | 100.0 | 1×SO4; 1×AIZ; 1×BME; | |||
| The MAP kinase JNK3 as target for halogen bonding | monomer | 100.0 | 1×3WH; 1×CL; | |||
| Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-rep… | monomer | 100.0 | 1×JBI; | |||
| Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-te… | monomer | 100.0 | 1×C0M; | |||
| Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor | monomer | 100.0 | 1×BME; 1×EDO; 1×B9K; | |||
| Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor | monomer | 100.0 | 1×KBI; 1×GOL; | |||
| JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin… | monomer | 100.0 | 1×J67; | |||
| JNK3 bound to piperazine amide inhibitor, SR2774. | monomer | 98.72 | 1×JK3; 5×EDO; | |||
| Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic prop… | monomer | 100.0 | 1×34I; | |||
| JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indoli… | monomer | 100.0 | 1×J72; | |||
| Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-car… | monomer | 100.0 | 1×33A; | |||
| Crystal structure of human Jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor | monomer | 100.0 | 1×SNB; | |||
| Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-f… | monomer | 100.0 | 1×738; | |||
| Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor | monomer | 100.0 | 1×446; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7yl1.1.A | monomer | 0.83 | 1×J6F; | 100.00 | ||